Key Performance
More- Earnings Score: 41
- Momentum Score: 19
- True Yield: N/A
- Financial Health Score: 9
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties. AstroNova is being acquired by Arcline Investment Management for $29.00 per share, Simulations Plus is being sold to Altaris affiliates for $18.50 per share, and Olin Corporation is merging with Huntsman Corporation. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.
06/23/2026, 9:37 PM • GlobeNewswire
The DJS Law Group has announced an investigation into Simulations Plus, Inc. (NASDAQ: SLP) on behalf of investors, focusing on whether the company issued misleading statements or failed to disclose material information to investors. The law group is seeking shareholders who suffered losses to participate in the investigation.
06/18/2026, 4:29 PM • Benzinga
Major M&A activity includes Fox Corp acquiring Roku for $22 billion, Salesforce buying Fin for $3.6 billion, Yum! Brands selling Pizza Hut to LongRange Capital for $1.5 billion, and Nuvei acquiring Payoneer for $2.75 billion. Additionally, Domo is pursuing a strategic transaction, and two companies filed for Chapter 11 bankruptcy.
06/18/2026, 2:05 PM • Benzinga
Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential violations of federal securities laws and breaches of fiduciary duties. The investigations concern Simulations Plus' sale to Altaris for $18.50 per share, Roku's sale to Fox Corporation for $96.00 cash plus 0.9693 Fox shares per share, and TruBridge's sale to Inventurus Knowledge Solutions for $26.25 per share. The firm is seeking increased consideration, additional disclosures, and other relief on behalf of shareholders.
06/16/2026, 9:04 PM • GlobeNewswire
The Schall Law Firm is investigating Simulations Plus, Inc. (NASDAQ: SLP) for potential securities law violations, focusing on whether the company issued false or misleading statements or failed to disclose material information to investors. The firm is seeking shareholders who suffered losses to participate in the class action lawsuit.
06/16/2026, 5:31 PM • Benzinga
Brodsky & Smith law firm is investigating four merger transactions to determine whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Simulations Plus ($18.50/share), Roku ($160.00/share), TruBridge ($26.25/share), and Organon ($14.00/share).
06/16/2026, 3:56 PM • GlobeNewswire
Why Shares in Simulation Plus Soared Today
Simulation Plus shares surged 11.24% after announcing a definitive acquisition agreement by investment company Altaris for $18.50 per share, representing a 26% premium to the 60-day volume-weighted average price. The all-cash transaction was unanimously approved by the board and is expected to close in Q4 2026. Altaris plans to combine Simulation Plus with its existing drug discovery software company, Chemical Computing Group.
06/16/2026, 1:04 PM • The Motley Fool
Shareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) for potential securities law violations and breach of fiduciary duties. The investigation follows significant stock declines triggered by disappointing revenue guidance in June 2025 (24% drop) and poor Q3 fiscal 2025 results including a $67.3 million net loss and $77.2 million impairment charge in July 2025 (26% drop). The company subsequently dismissed its auditor, Grant Thornton LLP, citing unresolved matters in segment reporting and internal controls.
06/05/2026, 6:04 PM • GlobeNewswire
Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) for potential securities law violations and breach of fiduciary duties. The investigation follows significant stock declines triggered by disappointing revenue guidance in June 2025 (24% drop) and poor Q3 fiscal 2025 results including a $67.3 million net loss and $77.2 million impairment charge in July 2025 (26% drop). The company subsequently dismissed its auditor, Grant Thornton LLP, citing unresolved issues with segment reporting and internal controls.
06/02/2026, 7:18 PM • GlobeNewswire
Global Biosimulation Market Poised for Phenomenal Expansion at a CAGR of ~17% by 2034 | DelveInsight
The biosimulation market is experiencing robust growth, projected to expand from USD 4.7 billion in 2025 to USD 20 billion by 2034 at a CAGR of ~17%. Growth is driven by increasing adoption of model-informed drug development (MIDD), rising complexity of modern therapeutics, regulatory support from FDA and EMA, and the shift toward virtual clinical trials and precision medicine. North America leads the market with 44.24% share, while Asia-Pacific emerges as a major growth contributor.
04/27/2026, 1:00 PM • GlobeNewswire
Certara Strategic Business Divestiture Comes At Right Time, Says Analyst
Certara announced the sale of its Regulatory and Medical Writing business to Veristat for up to $135 million. The divestiture is expected to close in Q2 2026 and will allow the company to focus on its Model-Informed Drug Development platform. Analysts view this as strategically positive timing, with William Blair noting it removes an overhang and provides capital for reinvestment in core biosimulation platforms.
04/22/2026, 3:23 PM • Benzinga
U.S. stock futures fell on Friday amid Middle East tensions over Iran-Israel ceasefire violations and ahead of March CPI data release. Major indices traded lower with the Dow, S&P 500, and Nasdaq 100 all declining slightly. Crude oil surged 2.31% to $100.13/barrel due to geopolitical concerns. Key gainers included Taiwan Semiconductor (up 1.81% on strong Q1 revenue), Simulations Plus (up 13.24% on better-than-expected results), and Urban-gro (up 12.31% on new strategy). Analysts remain cautiously optimistic about 2026 earnings growth despite headwinds from energy shocks and inflation.
04/10/2026, 8:46 AM • Benzinga
U.S. stock futures fell on Friday amid Middle East tensions over Iran-Israel ceasefire violations and ahead of March CPI data release. Major indices traded lower with the Dow, S&P 500, and Nasdaq 100 all declining slightly. Crude oil surged 2.31% to $100.13/barrel due to geopolitical concerns. Key gainers included Taiwan Semiconductor (up 1.81% on strong Q1 revenue), Simulations Plus (up 13.24% on better-than-expected results), and Urban-gro (up 12.31% on new strategy announcement).
04/10/2026, 5:13 AM • Benzinga
The Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc. (NASDAQ: SLP) for allegedly issuing materially misleading business information. The company missed earnings expectations in Q3 2025, reporting $20.4 million in sales versus a consensus estimate of $20.9 million, causing the stock to plummet 25.75% on July 15, 2025. The firm is preparing a class action lawsuit to recover investor losses.
02/10/2026, 2:37 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc. (NASDAQ: SLP) for allegedly issuing materially misleading business information. The company missed earnings expectations in Q3 2025, reporting $20.4 million in sales versus a consensus estimate of $20.9 million, causing the stock to plummet 25.75% on July 15, 2025. Investors who suffered losses are encouraged to join a prospective class action lawsuit.
02/05/2026, 7:40 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/23/2026
Company Profile
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.